Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
Can J Cardiol. 2013 Aug;29(8):934-9. doi: 10.1016/j.cjca.2013.01.008. Epub 2013 Apr 24.
Next-generation sequencing (NGS) is nearing routine clinical application, especially for diagnosis of rare monogenic cardiovascular diseases. But NGS uncovers so much variation in an individual genome that filtering steps are required to streamline data management. The first step is to determine whether a potential disease-causing variant has been observed previously in affected patients.
To facilitate this step for lipid disorders, we developed the Western Database of Lipid Variants (WDLV) of 2776 variants in 24 genes that cause monogenic dyslipoproteinemias, including conditions characterized primarily by either high or low low-density lipoprotein cholesterol, high or low high-density lipoprotein cholesterol, high triglyceride, and some miscellaneous disorders. We incorporated quality-control steps to maximize the likelihood that a listed mutation was disease causing.
The details of each mutation found in a dyslipidemia, together with a mutation map of the causative genes, are shown in graphical display items.
WDLV will help clinicians and researchers determine the potential pathogenicity of mutations discovered by DNA sequencing of patients or research participants with lipid disorders.
下一代测序(NGS)即将常规应用于临床,尤其是用于诊断罕见的单基因心血管疾病。但是 NGS 会在个体基因组中发现如此多的变异,因此需要过滤步骤来简化数据管理。第一步是确定个体基因组中潜在的致病变异是否先前在受影响的患者中观察到过。
为了便于脂质疾病的这一步骤,我们开发了西方脂质变异数据库(WDLV),其中包含 24 个基因中的 2776 个变异,这些基因导致单基因脂质代谢异常,包括主要表现为低或高低密度脂蛋白胆固醇、高或低高密度脂蛋白胆固醇、高甘油三酯以及一些杂类疾病的病症。我们纳入了质量控制步骤,以最大限度地提高列出的突变是致病的可能性。
以图形显示项的形式展示了在血脂异常中发现的每个突变的详细信息,以及致病基因的突变图谱。
WDLV 将帮助临床医生和研究人员确定通过对患有脂质代谢紊乱的患者或研究参与者的 DNA 测序发现的突变的潜在致病性。